Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug

Novo Nordisk A/S (NYSE:NVO) on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD) outcomes trial.

The study evaluated the once-weekly injectable Ozempic (semaglutide 1.0 mg) in adults with type 2 diabetes and PAD, at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo.

The trial achieved its primary endpoint, with semaglutide 1.0 mg demonstrating a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline, compared to placebo at week 52.

Also Read: Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech

The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed, including ...